Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT02605486

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Conditions: Metastatic Breast Cancer (MBC)

Sex: Female

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE1, PHASE2

Enrollment: 46

Sponsor: Memorial Sloan Kettering Cancer Center

Location: Memorial Sloan Kettering Cancer Center Basking Ridge New Jersey

Summary

The purpose of this study is to test the safety and effectiveness of the investigational drug, palbociclib with bicalutamide for the treatment of triple negative, androgen receptor positive breast cancer.

Eligibility Criteria

Inclusion Criteria: A patient will be eligible for androgen receptor expression testing (STEP 1) if the following criteria are met: * Female * Pathologically confirmed invasive cancer of the breast * ER/PR status (ER or PR defined as positive if ≥1%; ER/PR is defined as negative if \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02605486). StuddyBuddy aggregates publicly available trial information.